Enanta Pharmaceuticals Inc · Q4 2024 earnings

Briefing

Reported financial results for the fiscal fourth quarter and year-ended September 30, 2024.

Enanta Pharmaceuticals reported a net loss of $28.8 million for the three months ended September 30, 2024, compared to a net loss of $28.1 million for the corresponding period in 2023. Total revenue was $14.6 million, which consisted of royalty revenue, compared to $18.9 million for the three months ended September 30, 2023. The company's cash, cash equivalents and marketable securities totaled $248.2 million at September 30, 2024.

• Announced positive data from a Phase 2a human challenge study of EDP-323, the RSV L-inhibitor.
• Made notable progress in advancing and expanding the immunology portfolio with the nomination of EPS-1421 as the lead development candidate for the KIT inhibition program.
• Introduced a second discovery stage program to develop oral STAT6 inhibitors for the treatment of type 2 immune driven diseases.
• Operations are supported by cash and marketable securities totaling $248.2 million at September 30, 2024, as well as continuing retained royalties.

Headline financials

Revenue & EPS history

Enanta expects that its current cash, cash equivalents and short-term marketable securities, as well as its continuing retained portion of royalty revenue, will continue to be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2027.